AbCellera Stock Soars on Positive Menopause Treatment Results
AbCellera's (ABCL) stock surged 32% to $9.12 on Monday after the company released positive Phase 2 trial results for its menopause treatment candidate, ABCL635.
The study involved 92 postmenopausal women who received either a single 600mg subcutaneous injection of ABCL635 or an inactive placebo.
The primary efficacy goals were met, indicating the treatment reduced hot flash frequency and severity compared to the placebo group.
Participants receiving ABCL635 experienced a decrease in moderate-to-severe episodes by 8.8 per day from their starting baseline, while those in the placebo group saw a reduction of 3.5 episodes.
The study followed a randomized, double-blind, placebo-controlled framework, which is considered the gold standard methodology for clinical research.